Search Results

Biotech Beach

Amicrobe, Inc., Developer of Novel Synthetic Biologics, Adds Fifth U.S. Patent to Intellectual Property Portfolio

Today, Amicrobe, Inc. announced the issue of U.S. Patent No. 11,285,189, entitled “Compositions and uses of locally applied antimicrobials with enhanced performance and safety.”

April 26, 2022

·

2 min read

Biotech Beach

Amicrobe, Inc. announces kilogram-scale GMP manufacturing of Amicidins - synthetic proteins to prevent and treat life-threatening infections

Amicrobe, Inc., designs and develops breakthrough biologics at the interface of materials science and biotechnology.

September 21, 2021

·

4 min read

Policy

Amicrobe, Inc., Developer Of Novel Technology For Antibiotic Resistance, Adds Safety Application To Intellectual Property Portfolio

The company announces filing of a PCT application focused on safety in the treatment of antibiotic resistant infections, as well as multiple international acceptances of its two foundational patents.

April 24, 2018

·

3 min read

Biotech Beach

Amicrobe Announces Receipt of $2.48M Award From CARB-X to Accelerate Development of Amicidin-Β For Treatment of Life-Threatening Infections in Surgery and Trauma

CSL Behring announced today that new data will be presented for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the company’s subcutaneous preventive therapy for hereditary angioedema (HAE) attacks.

October 25, 2017

·

5 min read